Published within
|«
«
|
...
|
109
|
110
|
111
|
112
|
113
|
114
|
115
|
116
|
117
|
...
|
»
»|
| Type |
Product title / description
|
Pub
|
Price |
CommentWire
|
In October 2010, Datamonitor attended the 35th congress of the European Society of Medical Oncology, during which results were presented showing that GSK2118436, GlaxoSmithKline's BRAF kinase inhibitor, reduced the overall size of brain metastasis in almost all patients. However, as this success has so far been proved only in early phase trials, GSK must prove this efficacy through mature data.
Published By Datamonitor
|
18 Nov 2010 |
|
CommentWire
|
Merck & Co. has announced that the DEFINE trial has met both its primary and secondary endpoints in lipid-level modification. Furthermore, safety data for anacetrapib dismissed a torcetrapib-like increase in cardiovascular events. The results allow Merck to progress into a large outcomes trial and will restore confidence in the CETP inhibitor class.
Published By Datamonitor
|
22 Nov 2010 |
|
CommentWire
|
RNAi-based drugs were widely viewed as the next big thing after monoclonal antibodies; however, the initial wave of interest seems to be slowing down, largely due to financial constraints. Novartis and Roche recently ended their respective research in this field, highlighting the pharmaceutical industry's immediate need to boost its top line.
Published By Datamonitor
|
25 Nov 2010 |
|
CommentWire
|
The European Medicines Agency's latest draft guidelines on monoclonal antibodies offer some flexibility for producers, but development costs are still expected to be high. With the instructions likely to be interpreted on a case-by-case basis, communication with the agency will be critical for success.
Published By Datamonitor
|
30 Nov 2010 |
|
Expert View
|
Five companies account for approximately 80% of total global vaccine sales: Sanofi Pasteur, Merck & Co., GlaxoSmithKline, Pfizer, and Novartis. The key reason for this oligopoly is the high barrier to entry for smaller players, which usually have limited manufacturing capacity, and may also lack the resources and the distribution networks required for vaccine development.
Published By Datamonitor
|
01 Dec 2010 |
|
Expert View
|
Prior to 2000, vaccines were generally regarded as a commodity market with limited revenue opportunities. However, advances in vaccine technology, the launch of new vaccines, increased investment in research, a change of public opinion about vaccination, and more favorable legislation regarding vaccine injury compensation have contributed to their re-emergence as successful growth drivers.
Published By Datamonitor
|
01 Dec 2010 |
|
CommentWire
|
Following encouraging Phase III results, Teva's laquinimod is firmly in line to become the third approved oral treatment in relapsing-remitting multiple sclerosis. However, with the recent launch of the first oral multiple sclerosis therapy, Novartis's Gilenya, Teva will face a serious challenge in keeping hold of its market-leading multiple sclerosis share.
Published By Datamonitor
|
09 Dec 2010 |
|
Expert View
|
New data show that immediate treatment with Rituxan provides an impressive reduction in follicular lymphoma progression rates. These results could lead to a change in the management of newly diagnosed asymptomatic follicular lymphoma patients and increased uptake of Rituxan in the seven major markets.
Published By Datamonitor
|
13 Dec 2010 |
|
CommentWire
|
The proposed "enhanced co-operation mechanism," if approved, would allow some member states to move forward on developing a single EU patent. This could reduce costs and improve competitiveness in the pharma industry. However, unrest could be created among EU member states as Italy and Spain do not agree with the proposal or the commission's translation plans for the patent.
Published By Datamonitor
|
16 Dec 2010 |
|
Expert View
|
The UK's Department of Health has published its value-based pricing approach for medicines for consultation until March 2011. The proposed guidelines envisage different price thresholds for drugs based on the value that they deliver to the health service. While the cost watchdog's role would be changed, it would not be quite as diminished as first thought.
Published By Datamonitor
|
21 Dec 2010 |
|
|«
«
|
...
|
109
|
110
|
111
|
112
|
113
|
114
|
115
|
116
|
117
|
...
|
»
»|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.